AHA Cardiovascular Genome Phenome Study (CVGPS) Funding
The Cardiovascular Genome Phenome Study (CVGPS) is a collaborative effort, spearheaded by the American Heart Association (AHA), to accelerate the future of cardiovascular medicine. CVGPS combines the power of long-term population studies with the precision of molecular analysis to unravel key distinctions between and within subgroups of patients. The discoveries it generates will point the way toward better-targeted, safer, and more effective treatments, based on a deeper understanding of patients’ characteristics, including e.g. risk profiles and therapeutic needs.
The CVGPS is a collaboration among AHA, Boston University (BU) and the University of Mississippi Medical Center (UMMC), the academic coordinating center homes, respectively, of the Framingham Heart Study (FHS) and the Jackson Heart Study (JHS). The Jackson Heart Study also involves Jackson State University (JSU) and Tougaloo College (TC) as partner institutions.
Through the rich diversity of constituent participant/patient populations, CVGPS research will bring inter-individual and patient-to-patient differences into ever sharper focus for common diseases such as atherosclerosis and hypertension.
To accomplish the promise of the CVGPS, AHA is offering two funding opportunities to investigators:
- CVGPS Pathway Grants – funded at $250K/year for 2 years for a total of $500K
- CVGPS Grand Challenge Awards – funded at $500K for 4 years for a total of $2MM
The Letter of Application (LOA) for the CVGPS Pathway Grant is due in June. An LOA for the CVGPS Grand Challenge Award is due in October. A letter of application is required to ensure responsiveness to the unique nature of these programs. After peer reviewed, only invited applicant proposals will be accepted.
For more information about the desired characteristics, requirements for the application, letter of application and peer review criteria view the full Request for Applications - (PDF).